People · Operator
Named in public records as an officer, director or promoter · active 2009–2025 · Pharmaceuticals, Biotechnology, Other Technology, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Ardelyx, Inc. | — | Pharmaceuticals | Series D+ | $210.4M | $3.9B | 2016 |
| Sagimet Biosciences Inc. | — | Biotechnology | Series C | $166.6M | $2.4B | 2009 |
| Apexigen, Inc. | — | Biotechnology | Series C | $66.4M | $85.6M | 2023 |
| Maverix Biomics, Inc. | — | Other Technology | Series A | $8.0M | $221.8M | 2013 |
| Protein Metrics Inc. | — | Other | Pre-Seed | $950K | $22.0M | 2014 |
| Maxymune Therapeutics, Inc. | — | Biotechnology | Pre-Seed | $850K | $2.7M | 2025 |
| Alavita Pharmaceuticals Inc | — | Biotechnology | Pre-Seed | $600K | $33.1M | 2009 |
Gordon Ringold at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Gordon Ringold on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David Mott | 2 | 9 |
| Richard Rodgers | 2 | 4 |
| Scott Smith | 1 | 16 |
| Beth Seidenberg | 1 | 15 |
| David Collier | 1 | 8 |
| Annalisa Jenkins | 1 | 8 |
| Robert Garland | 1 | 7 |
| George Lee | 1 | 6 |
| Richard Lerner | 1 | 5 |
| KAREN LIU | 1 | 4 |
| James Young | 1 | 4 |
| Andrew Yang | 1 | 4 |
| Jeremy Caldwell | 1 | 4 |
| Peter G. Schultz | 1 | 3 |
| William Rutter | 1 | 3 |
| Kenneth Fong | 1 | 3 |
| David Rosenbaum | 1 | 3 |
| Christopher Becker | 1 | 3 |
| Amy Wong | 1 | 2 |
| Dan Zabrowski | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.